New scan could tell doctors if breast cancer drugs will work before starting treatment
NCT ID NCT02827877
Summary
This study is testing a special PET scan to see if it can predict how well a patient's HER2-positive breast cancer will respond to two targeted drugs (trastuzumab and pertuzumab) given before surgery. Researchers will give 18 women with locally advanced breast cancer a scan using a radioactive tracer that attaches to the cancer cells. They will then see if the scan results match how well the cancer actually responds to the drug treatment and is removed during surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.